In addition, clinical trials with AAV carrying cardiac myosin‐binding protein C (MYBPC3) in hypertrophic cardiomyopathy (HCM), lysosome‐associated membrane protein 2b (LAMP2b) in Danon disease and plakophilin 2a (PKP2A) in arrhythmogenic right ventricular cardiomyopathy (ARVC) patients are currently ongoing (see below, Table 1). The gene discussed is MYBPC3; the disease is arrhythmogenic right ventricular cardiomyopathy.